Noxopharm (ASX:NOX) starts manufacturing SOF-SKN™ to support planned clinical trial targeting cutaneous lupus erythematosus, with low supply chain risks and strong stability. bit.ly/4vBN1Xw
Noxopharm (ASX:NOX) Sofra™ platform data is to be presented by CSL at top global influenza conference, highlighting its potential to enhance self-amplifying mRNA vaccine delivery. bit.ly/4dBMk9k
#Biotech #Immunotherapy
Noxopharm has announced positive results from InhaTarget Therapeutics, a company with a unique inhalation-based delivery system that is testing Sofra™ technology platform assets.
Read the announcement here: www.noxopharm.com/pdf/deb770c3...
Noxopharm (ASX:NOX) advances US FDA pre-IND strategy for SOF-SKN™, targeting $3.3B+ autoimmune skin disease market. Engages global CRO Novotech to boost regulatory and commercial potential. #Biotech #DrugDevelopment bit.ly/49dSDyk
New data from Noxopharm (ASX:NOX) shows its Sofra™ platform can amplify TLR8 immune response 200-fold, unlocking potent new cancer immunotherapy potential in a $185B market by 2035. bit.ly/3Pl6Gvy
#biotech #ImmunoOncology
New data demonstrates SOF-16, the active ingredient in SOF-SKN, effectively blocks inflammation in blood and joint fluid samples from lupus and rheumatoid arthritis patients. This supports further development of SOF-SKN for autoimmune diseases. Announcement: www.noxopharm.com/pdf/e6d6d6bf...
Noxopharm’s latest quarterly is now out, with news of an MoU with US company Tezcat Biosciences, signalling a mutual intent to deepen collaboration in the months ahead and building on the success of an ongoing collaboration.
Read the quarterly here: www.noxopharm.com/pdf/2e566eae...
Professor Michael Gantier @gantierlab.bsky.social from @hudsonresearch.bsky.social, Noxopharm’s strategic partner, will be a keynote speaker at a free international webinar on 17 June.
More details including specific timings and a registration link can be found here: sciforum.net/event/Pharma...
Check out the latest from Noxopharm CEO Dr Olivier Laczka as he outlines the significant potential of the company's technology platform: www.proactiveinvestors.com.au/companies/ne...
Noxopharm has announced promising new data in support of a future human trial for SOF-SKN™, the company’s cutaneous lupus drug candidate, confirming several important characteristics of the drug and representing a positive step in its refinement.
Read more here: www.noxopharm.com/pdf/a094654d...
bit.ly
www.noxopharm.com
www.noxopharm.com
www.noxopharm.com
bit.ly
www.noxopharm.com
bit.ly
bit.ly
sciforum.net
Noxopharm Limited CEO Olivier Laczka talked with Proactive about the company's Sofra™ technology platform and how its discovery around Toll-like...
